Author: Samedan Ltd

Lubrizol Licenses Award-Winning Apisolex Excipient to Welton Pharma to Develop a Novel Cancer Therapeutic

CLEVELAND, US – 21 June 2023 – The Lubrizol Corporation announces
the licensing of its novel excipient polymer technology, Apisolex
excipient, to Welton Pharma (Welton). The license allows Welton to use
the Apisolex excipient worldwide to develop and commercialise a novel
formulation of SN-38 to treat colorectal and associated
gastro-intestinal cancers.

Read More

Allucent Selects THREAD to Power Patient Direct Trials Offering

Cary, US – 20 June 2023 – Global biopharmaceutical services
provider Allucent has partnered with THREAD, an innovative decentralised
clinical trial (DCT) and electronic clinical outcomes assessment (eCOA)
technology provider, to launch Allucent Patient Direct Trials. The new
offering brings advanced technologies and development and regulatory
expertise to small and emerging biotechnology companies to support them
in designing and overseeing customised decentralised clinical trial

Read More

Veristat Acquires European Medical Writing Consultancy

Southborough, US – 12 June 12 2023 – Veristat, a
scientific-minded global clinical research organization (CRO), has
acquired Scinopsis, a European medical writing consultancy with a
17-year track record of delivering regulatory and medical communication
documents of the highest quality to the biopharmaceutical industry. The
acquisition strengthens Veristatís ability to meet growing client demand
in one of its highest-valued service areas as the range of clinical
trial content expands and the importance of regulatory documentation

Read More